Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression

RecruitingOBSERVATIONAL
Enrollment

228

Participants

Timeline

Start Date

December 29, 2021

Primary Completion Date

October 28, 2026

Study Completion Date

February 28, 2027

Conditions
Major Depressive Disorder
Interventions
DEVICE

Aversive stimuli

Electrotactile stimulation will be used as the aversive stimulus. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model DS71 has been safely implemented in studies with previously MGH-approved IRB's (Milad et al., 2013).

DRUG

PET radiotracer

"A Nociceptin/Orphanin FQ (N/OFQ) peptide tracer (\[11C\] NOP-1A) will be used as the PET radiotracer. Approximately 10 mCi of this tracer will be delivered intravenously as a slow bolus over 60 seconds with beginning of the PET imaging acquisition. Approximately 60 ml of blood will be drawn from an artery throughout the dynamic PET acquisition in order to measure the blood N/OFQ levels."

Trial Locations (1)

02478

RECRUITING

McLean Hospital, Belmont

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Mclean Hospital

OTHER